Macroaxis: Personalized Investing
Simple Personalized Investing

SP 500   1,651   4.84  Index Moved Down -0.29%
GILD AMGN BIIB CELG Cars ISP Conservative Macroaxis Picks 
United States GSPC USD ...  |  Optimize Portfolios


Processing
Collecting data for ALXN

Alexion quote and profile

 
 Companies |  Insiders  | Dashboard  
     
99.88
  
STOCK
(0.69)  Macroaxis: -0.69 Down   0.69%  
Year To Date
81.28120
Last 1 Month(s)
89.23108
Trading Day 
98.0101
May 23 2013 

Diversification Suggestion

Use Alexion to protect against small markets fluctuations. The stock experiences moderate downward daily trend and can be a good diversifier
Analyze Alexion Pharmaceuticals Trend or Check current 30 days Alexion correlation with market (S&P 500)
1 Month Beta 1.86  
Highest Price:  
Lowest Price:  
107.86  
89.23  
May 14 2013 
April 24 2013 
As market goes up, the company is expected to significantly outperform it. However, if the market returns are negative, Alexion will likely underperform.
Alexion Pharmaceuticals Inc Large BetaAlexion Pharmaceuticals Beta Legend
ALXN United States Nasdaq
Alexion Pharmaceuticals Inc
Healthcare
Biotechnology
Benchmark S&P 500
http://www.alexionpharm.com
Contact Number: 203. 272. 2596
Currency: USD - US Dollar
Traded on NASDAQ
    
Current Valuation19.21 B
Shares Outstanding195.15 M
Number of Shares Shorted4.58 M
Revenue1.23 B
 United States Nasdaq   0.97 % Macroaxis: 0.97 Moved Up  
 
 United States Russel   0.21 % Macroaxis: 0.21 Moved Up  
 
 United States SP 500   0.29 % Macroaxis: 0.29 Moved Down  
 
 United States NYSE   0.44 % Macroaxis: 0.44 Moved Down  
 
 thisRed ALXN ALXN agains markets  0.69 % Macroaxis: 0.69 Moved Down  
 
Compare to Competition Get Alpha   Get Advice

Alexion Leadership

Leonard MD Co-Founder, CEO, Treasurer and Director
Leonard Bell CEO, Treasurer, Director
Max Link Independent Chairman of the Board, Ph.D
Vikas Sinha CFO, Senior Vice President

Alexion Price and Market Media

The median price of Alexion for the period between Tue, Apr 23, 2013 and Thu, May 23, 2013 is 98.82 with a coefficient of variation of 4.38. The daily time series for the period is distributed with a sample standard deviation of 4.35, arithmetic mean of 99.32, and mean deviation of 3.29. The Stock received substential amount of media coverage during this period.
Alexion         SP 500
Price Growth (%)
 
1
Forbes Earnings Preview Alexion Pharmaceuticals Inc.04/24/2013Macroaxis: Forbes News
2
Alexion Pharmaceuticals Rating Reiterated by Wells Fargo04/26/2013Macroaxis: News
3
Alexion Pharmaceuticals Given New 123.00 Price Target at UBS...05/01/2013Macroaxis: News
4
Alexion Pharmaceuticals Rating Lowered to Sell at Thomson Re...05/03/2013Macroaxis: News
5
Alexion to Present at the BofA Merrill Lynch 2013 Healthcare...05/09/2013Businesswire News
6
Alexion Pharmaceuticals Receives Outperform Rating from Zack...05/15/2013Macroaxis: News
7
New Report Available Alexion Pharmaceuticals Inc. Product Pi...05/22/2013Macroaxis: News

Alexion Summary

Alexion Pharmaceuticals Inc [ALXN] is traded on NASDAQ in USA. It is located in Alexion Pharmaceuticals, Inc.Cheshire, CT and employs 1,373 people. The company currently falls under 'Large-Cap' category with current market capitalization of 19.63 B. Alexion Pharmaceuticals Inc conducts business under Healthcare sector and is part of Biotechnology industry. This company has 195.15 M outstanding shares of which 4.58 M shares are presently shorted by private and institutional investors with about 2.3 trading days to cover.
Alexion Pharmaceuticals, Inc., a biopharmaceutical company, engages in the development and commercialization of lifetransforming therapeutic products. more
Past Market
Over 30
Days
8
Out Of
100
 
Chance of
Less
Than
%
 
Follow Alexion with Macroaxis syndicated feed, custom widget, or your favorite custom stock ticker
Add To Reader
 
Add Alexion to your reader
 

Alexion Research Report

Alexion vs. Gilead

Correlation analysis and fundamentals comparison between Alexion Pharmaceuticals and Gilead Sciences

Alexion Executives

Scott Rollins Co-Founder
Stephen Squinto Co-Founder, Chief Global Operations Officer and Executive VP, Ph.D
CA, MBA CFO and Executive VP

Alexion Directors

Larry Mathis Independent Director
MD Madri Co-Founder, Director, Member of Compensation Committee and Member of Pharmaceutical Compliance and Quality Committee
Alvin Parven Independent Director
Joseph Madri Independent Director
Andreas Rummelt Independent Director, Ph.D

Alexion Fundamentals

EBITDA vs Total Asset
Current Ratio vs Price to Earning
EBITDA vs Number of Shares Shorted
Cash per Share vs Price to Earning

Alexion vs Competition

Alexion vs. Gilead Sciences Inc
Alexion vs. Amgen Inc
Alexion vs. Biogen Idec Inc
Alexion vs. Celgene Corporation
Alexion vs. Regeneron Pharmaceuticals Inc
Alexion vs. Vertex Pharmaceuticals Incorporated
Alexion vs. BioMarin Pharmaceutical Inc
Alexion vs. Illumina Inc
Alexion vs. Onyx Pharmaceuticals Inc

Alexion May 23 2013 Opportunity Range

Downside Deviation2.01
Information Ratio0.0788
Maximum Drawdown13.97
Value At Risk(2.79)
Potential Upside6.06

 
Analytics
Risk Adjusted Returns Landscape
Live Efficient Frontier
Market Correlation Analysis
Watchlist Analysis
Financial Content
Portfolio Estimation and Projections
Portfolio Theme Builder
 
 
Research Modules
Equities Backtesting Analysis
Instant Retirement Optimizer
Cross-portfolio RSS and Mobile Access
Company, fund, and ETF Directory
Financial Advisor Directory
Insider and Manager Directory
Wealth Management
 Gadgets, Widgets, and Apps          
  
 
Services And Technology
Frequently Asked Questions
Quick Product Tour
Product Technology Overview
Solution Methodology
Plans and Pricing
 
Free Investor Tools
World Market Correlations
Instant Equity Comparator
Watchlist Analysis
Position Suggestions
Equity Alpha Analysis
 
About Us
About Macroaxis
Contact Us
Product Terms Of Use
Service Privacy Policy
Advertising Opportunities
Content

Thanks for checking out Macroaxis

Tell us what you like and what you don't like. We promise we'll not only listen but write you back

Contact Us
Macroaxis is user-driven community of investors. We appreciate any feedback or comment you can provide. Please fill out our quick survey to help us provide your with a better service and user experience

Fill Out Quick Survey
Most of the functionality on our site is free to use. However we do provide premium service to sophisticated investors. Our premium subscription will give you unprecedented capabilities to optimize your portfolios using robust financial analysis toolkit, fast mean-variance optimization engine, and proven portfolio theory

Go Premium